{"nctId":"NCT00025259","briefTitle":"Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease","startDateStruct":{"date":"2002-09"},"conditions":["Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma","Childhood Mixed Cellularity Classical Hodgkin Lymphoma","Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma","Childhood Nodular Sclerosis Classical Hodgkin Lymphoma","Stage I Childhood Hodgkin Lymphoma","Stage II Childhood Hodgkin Lymphoma","Stage III Childhood Hodgkin Lymphoma","Stage IV Childhood Hodgkin Lymphoma"],"count":1734,"armGroups":[{"label":"Arm I (Patients off-therapy before callback-Induction only)","type":"EXPERIMENTAL","interventionNames":["Biological: Bleomycin Sulfate","Drug: Cyclophosphamide","Drug: Doxorubicin Hydrochloride","Drug: Etoposide","Biological: Filgrastim","Drug: Prednisone","Drug: Vincristine Sulfate Liposome"]},{"label":"Arm II (RER with CR [ABVE-PC, IFRT])","type":"EXPERIMENTAL","interventionNames":["Biological: Bleomycin Sulfate","Drug: Cyclophosphamide","Drug: Doxorubicin Hydrochloride","Drug: Etoposide","Biological: Filgrastim","Radiation: Involved-Field Radiation Therapy","Drug: Prednisone","Drug: Vincristine Sulfate Liposome"]},{"label":"Arm III (RER with CR [ABVE-PC])","type":"EXPERIMENTAL","interventionNames":["Biological: Bleomycin Sulfate","Drug: Cyclophosphamide","Drug: Doxorubicin Hydrochloride","Drug: Etoposide","Biological: Filgrastim","Drug: Prednisone","Drug: Vincristine Sulfate Liposome"]},{"label":"Arm IV (RER with less than CR [ABVE-PC, IFRT])","type":"EXPERIMENTAL","interventionNames":["Biological: Bleomycin Sulfate","Drug: Cyclophosphamide","Drug: Doxorubicin Hydrochloride","Drug: Etoposide","Biological: Filgrastim","Radiation: Involved-Field Radiation Therapy","Drug: Prednisone","Drug: Vincristine Sulfate Liposome"]},{"label":"Arm V (RER with PD)","type":"EXPERIMENTAL","interventionNames":["Biological: Bleomycin Sulfate","Drug: Cyclophosphamide","Drug: Doxorubicin Hydrochloride","Drug: Etoposide","Biological: Filgrastim","Drug: Prednisone","Drug: Vincristine Sulfate Liposome"]},{"label":"Arm VI (SER [DECA, ABVE-PC, IFRT])","type":"EXPERIMENTAL","interventionNames":["Biological: Bleomycin Sulfate","Drug: Cisplatin","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Etoposide","Biological: Filgrastim","Radiation: Involved-Field Radiation Therapy","Drug: Prednisone","Drug: Vincristine Sulfate Liposome"]},{"label":"Arm VII (SER [ABVE-PC, IFRT])","type":"EXPERIMENTAL","interventionNames":["Biological: Bleomycin Sulfate","Drug: Cyclophosphamide","Drug: Doxorubicin Hydrochloride","Drug: Etoposide","Biological: Filgrastim","Radiation: Involved-Field Radiation Therapy","Drug: Prednisone","Drug: Vincristine Sulfate Liposome"]}],"interventions":[{"name":"Bleomycin Sulfate","otherNames":["Blanoxan","BleMomycine","Blenoxane","Bleo-cell","Bleo-S","Bleocin","Bleolem","Bleomycin Sulfas","Bleomycin Sulphate","Blexane","Oil Bleo"]},{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"]},{"name":"Cyclophosphamide","otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR- 138719"]},{"name":"Cytarabine","otherNames":[".beta.-Cytosine arabinoside","1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-.beta.-D-Arabinofuranosylcytosine","1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-Beta-D-arabinofuranosylcytosine","1.beta.-D-Arabinofuranosylcytosine","2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-","2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-","Alexan","Ara-C","ARA-cell","Arabine","Arabinofuranosylcytosine","Arabinosylcytosine","Aracytidine","Aracytin","Aracytine","Beta-Cytosine Arabinoside","CHX-3311","Cytarabinum","Cytarbel","Cytosar","Cytosar-U","Cytosine Arabinoside","Cytosine-.beta.-arabinoside","Cytosine-beta-arabinoside","Erpalfa","Starasid","Tarabine PFS","U 19920","U-19920","Udicil","WR-28453"]},{"name":"Dexamethasone","otherNames":["Aacidexam","Adexone","Aknichthol Dexa","Alba-Dex","Alin","Alin Depot","Alin Oftalmico","Amplidermis","Anemul mono","Auricularum","Auxiloson","Baycuten","Baycuten N","Cortidexason","Cortisumman","Decacort","Decadrol","Decadron","Decalix","Decameth","Decasone R.p.","Dectancyl","Dekacort","Deltafluorene","Deronil","Desamethasone","Desameton","Dexa-Mamallet","Dexa-Rhinosan","Dexa-Scheroson","Dexa-sine","Dexacortal","Dexacortin","Dexafarma","Dexafluorene","Dexalocal","Dexamecortin","Dexameth","Dexamethasonum","Dexamonozon","Dexapos","Dexinoral","Dexone","Dinormon","Fluorodelta","Fortecortin","Gammacorten","Hexadecadrol","Hexadrol","Lokalison-F","Loverine","Methylfluorprednisolone","Millicorten","Mymethasone","Orgadrone","Spersadex","Visumetazone"]},{"name":"Doxorubicin Hydrochloride","otherNames":["5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)","ADM","Adriacin","Adriamycin","Adriamycin Hydrochloride","Adriamycin PFS","Adriamycin RDF","ADRIAMYCIN, HYDROCHLORIDE","Adriamycine","Adriblastina","Adriblastine","Adrimedac","Chloridrato de Doxorrubicina","DOX","DOXO-CELL","Doxolem","Doxorubicin.HCl","Doxorubin","Farmiblastina","FI 106","FI-106","hydroxydaunorubicin","Rubex"]},{"name":"Etoposide","otherNames":["Demethyl Epipodophyllotoxin Ethylidine Glucoside","EPEG","Lastet","Toposar","Vepesid","VP 16-213","VP-16","VP-16-213"]},{"name":"Filgrastim","otherNames":["Filgrastim XM02","G-CSF","Neupogen","r-metHuG-CSF","Recombinant Methionyl Human Granulocyte Colony Stimulating Factor","rG-CSF","Tbo-filgrastim","Tevagrastim"]},{"name":"Involved-Field Radiation Therapy","otherNames":["IFRT","Involved field radiotherapy"]},{"name":"Prednisone","otherNames":[".delta.1-Cortisone","1, 2-Dehydrocortisone","Adasone","Cortancyl","Dacortin","DeCortin","Decortisyl","Decorton","Delta 1-Cortisone","Delta-Dome","Deltacortene","Deltacortisone","Deltadehydrocortisone","Deltasone","Deltison","Deltra","Econosone","Lisacort","Meprosona-F","Metacortandracin","Meticorten","Ofisolona","Orasone","Panafcort","Panasol-S","Paracort","PRED","Predicor","Predicorten","Prednicen-M","Prednicort","Prednidib","Prednilonga","Predniment","Prednisonum","Prednitone","Promifen","Servisone","SK-Prednisone"]},{"name":"Vincristine Sulfate Liposome","otherNames":["Marqibo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with newly diagnosed, pathologically confirmed Hodgkin disease (all histologies) are eligible for this protocol if they meet the following clinical stage guidelines:\n\n  * All Stage IB regardless of bulk disease\n  * All Stage IIB regardless of bulk disease\n  * Stage IA only with bulk disease\n  * Stage IIA only with bulk disease\n  * All Stage IAE, IIAE regardless of bulk disease\n  * All Stage IIIA, IIIAE, IIIAS, IIIAE+S regardless of bulk disease\n  * All Stage IVA, IVAE regardless of bulk disease\n* May not be staged by laparotomy alone\n\n  * Surgically staged patients must also have presurgical staging\n* Bilirubin no greater than 1.5 times normal\n* SGOT or SGPT less than 2.5 times normal\n* Creatinine no greater than 1.5 times normal\n* Creatinine clearance greater than 40 mL/min\n* Radioisotope glomerular filtration rate greater than 70 mL/min\n* Shortening fraction at least 27% by echocardiogram\n* Ejection fraction at least 50% by MUGA\n* No pathologic prolongation of QTc interval on 12-lead electrocardiogram\n* FEV\\_1/FVC greater than 60% by pulmonary function test\n* Pulse oximetry greater than 94%\n* No evidence of dyspnea at rest\n* No exercise intolerance\n* Adequate venous access\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No prior chemotherapy\n* At least 1 month since prior corticosteroids except prednisone for respiratory distress\n* No prior radiotherapy","healthyVolunteers":false,"sex":"ALL","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival","description":"Probability of event-Free survival which is defined as the time from study entry to treatment failure (disease progression, disease recurrence, biopsy positive residual after completion of all protocol therapy), occurrence of a second malignant neoplasm, or death from any cause. Patients without report of such events where censored at last contact.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":null},{"groupId":"OG001","value":"0.87","spread":null},{"groupId":"OG002","value":"0.84","spread":null},{"groupId":"OG003","value":"0.87","spread":null},{"groupId":"OG004","value":"0.70","spread":null},{"groupId":"OG005","value":"0.79","spread":null},{"groupId":"OG006","value":"0.74","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Response Assessed by Modified RECIST Criteria","description":"Number of participants with complete response and very good partial response at the end of protocol therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"370","spread":null},{"groupId":"OG002","value":"380","spread":null},{"groupId":"OG003","value":"538","spread":null},{"groupId":"OG004","value":"29","spread":null},{"groupId":"OG005","value":"105","spread":null},{"groupId":"OG006","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Grade 3 or 4 Non-hematologic Toxicity","description":"Occurrence of any grade 4 non-hematologic toxicity or grade 3 non-hematologic toxicity which doesn't respond to treatment within 7 days despite recommended therapy modification, or toxic death, which is any death primarily attributable to treatment. Grade 3 is defined to be severe or medically significant but not immediate life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 refers to toxicities with life-threatening consequences; urgent intervention indicated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"153","spread":null},{"groupId":"OG002","value":"130","spread":null},{"groupId":"OG003","value":"216","spread":null},{"groupId":"OG004","value":"11","spread":null},{"groupId":"OG005","value":"62","spread":null},{"groupId":"OG006","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Probability of overall survival which is defined as the time from study entry to death from any cause. Patients alive where censored at last contact.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null},{"groupId":"OG001","value":"0.98","spread":null},{"groupId":"OG002","value":"0.98","spread":null},{"groupId":"OG003","value":"0.98","spread":null},{"groupId":"OG004","value":"0.96","spread":null},{"groupId":"OG005","value":"0.93","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":38},"commonTop":["Neutrophil count decreased","Anemia","Platelet count decreased","Febrile neutropenia","White blood cell decreased"]}}}